in order to evaluate in a double-blind manner the therapeutic efficacy of selegiline in the treatment of late-phase parkinson 's disease , 19 patients with end-of-dose type fluctuations were randomized for a double-blind cross-over trial receiving either selegiline 10 mg or placebo .
C0030567
parkinson 's disease
C0036579
selegiline